Filter Results:
(990)
Show Results For
- All HBS Web
(990)
- People (4)
- News (256)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
Show Results For
- All HBS Web
(990)
- People (4)
- News (256)
- Research (615)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
- 14 May 2014
- News
(Re)moving the Needle
You wouldn't think that the lowly, annoying mosquito would have anything to teach researchers working on the cutting edge of drug delivery methodology, but you would be wrong. Have you ever noticed that you don't become aware of a... View Details
- Profile
Arjun Goyal
“marries a scientific eye for identifying precise populations in which therapies are effective, with a commercial appetite for successful drugs that need more time and money to prove their potential.” As part of a four-person clinical... View Details
- Profile
Hunter Goble
scientists in Harvard and MIT’s ecosystem. Through a self-matching process that Hunter describes as “speed dating,” he found two scientists from Boston’s Children’s Hospital developing “a novel drug delivery platform that increases the... View Details
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
biotech companies—as a function of cost, time, and failure modes—tend to risk pivot on one program, one clinical trial, one outcome,” he observes. “Our company is the leader in mining muscle biology for drug discoveries that translate... View Details
Keywords: Deborah Blagg
- 01 Sep 2008
- News
Mara Aspinall
higher efficacy rate — 80 percent or more. Is 80 percent efficacy unusual for drugs currently on the market? Across all patients and diseases, drug efficacy averages 50 percent, so half the time they bring... View Details
- 05 May 2020
- News
“Walking a Tightrope”
Kristof, most of which have focused on poverty in developing countries. But in the Pulitzer Prize-winning duo’s latest book, Tightrope: Americans Reaching for Hope, they turn their lens on working class communities in the United States—communities that have been... View Details
- 01 Dec 2022
- News
Road to Recovery
illegal-drug addictions totaled an estimated $700 billion in direct and indirect costs, according to a 2015 report from the National Institute on Drug Abuse. DynamiCare developed an app that provides financial rewards via a debit card... View Details
- Web
Sean Meng | MBA
intersection of technology and business: I caught the innovation bug during my time in San Diego working on a GABA(A) PAM pipeline for a CNS therapeutics startup. Immersed in this supportive startup culture, I saw firsthand how a drug... View Details
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Other Agencies Influence Approvals In the case of procedural legitimacy, the researchers found a strong influence from an unlikely source—the USDA's sister agency, the Food and Drug Administration. In the process of approving GMOs,... View Details
- 20 Aug 2014
- News
With No Time to Lose
into ALS research, and removed some critical barriers to the development of treatments. “Our focus, from the start, was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed with the disease in 2004, just weeks... View Details
Keywords: Margie Kelley
Stanley P. Goldstein
In 1969, Goldstein’s drug store chain, CVS, was acquired by Melville Corporation and soon became the conglomerate’s dominant retail establishment. Goldstein took the reins of Melville in 1987 and began a total restructuring program... View Details
Keywords: Retail
- 24 Apr 2014
- News
Building a better India through business and philanthropy
more than 30 countries, Mumbai-based Piramal Group comprises companies focused on health care, life sciences, drug discovery, health care information management, financial services, specialty-glass packaging, and real estate. Recently,... View Details
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers association, Frazier has led the... View Details
Keywords: by Bill George
- 07 Oct 2014
- News
Network Effect
was shocked by their advice. “They said, ‘Try three Advil a day. It might help. There are a few FDA-approved drugs for Alzheimer’s disease, and they won’t help,’” he recalls. McCance, a venture- capital pioneer with Greylock Partners, had... View Details
Keywords: Linda Kush
- 11 May 2021
- News
Pitching to Win
the five grand-prize winners. Goble is co-founder of Karivez Bio, a platform for transforming chronic disease treatment through improved drug delivery. Okrah is founder and CEO of Chaku Foods, a fast-moving consumer goods company based in... View Details
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic drugs (therapeutic proteins or “large-molecule drugs”) represent a substantial and growing share of the U.S. drug market, accounting... View Details
Keywords: Sean Silverthorne
- 22 Sep 2017
- News
The Epicenter of Miami’s Vice
PBS Hour dug deep into the scene's underworld and found that all roads lead to the Mutiny, this glitzy hotel in Coconut Grove that was a hub for celebrities and the epicenter of a global drug trade. Farzad spoke with the Bulletin's... View Details
- 01 Jun 1997
- News
Thomas C. Høegh
countries. Høegh explains that he always tries to include a philanthropic side to his artistic endeavors: "Among those employed in my productions in Norway were rehabilitated drug addicts from a special jobs program. Having this kind of... View Details
Keywords: Garry Emmons
- 01 Jun 2002
- News
Up to the Challenge: Lori Schock - Listen and Learn
insists, “it's theirs.” One opinion that was heard loud and clear during Schock's SA service was a call for a new prescription drug plan for HBS students. Schock was among student leaders who met with University health officials and the... View Details
Keywords: Kathleen Brill
- 24 Jun 2016
- News
Reinventing Pharma
2004) began her career as a research scientist. Eventually expanding her responsibilities into business development led her to HBS, where she hoped to solidify her understanding of the intersection of science and business. Following graduation, she joined Novartis,... View Details